Catherine Skari

A YEAR IN RETROSPECT | Global Public Health Achievements and Challenges in 2023

We applaud the remarkable strides in eradicating diseases and infections, such as ending the COVID-19 public health emergency and intensifying…

Read More »

wAIHA | Fostamatinib May Induce Durable Hemoglobin Response in Subset of Patients

Interestingly, this positive outcome was predominantly observed among participants hailing from North America, Australia, or Western Europe, while those from…

Read More »

SICKLE CELL DISEASE | FDA Approves Two Landmark Gene Therapies for the Treatment of the Disorder

The two therapies are Casgevy (exa-cel) by Vertex Pharmaceuticals and CRISPR Therapeutics – the world’s first drug to utilize the…

Read More »

NEWS | ICER Releases Draft Evidence Report on Treatment for Paroxysmal Nocturnal Hemoglobinuria

This preliminary draft marks the midpoint of ICER’s eight-month process of assessing these treatments, and the findings within this document…

Read More »

PHARMA NEWS | FDA Approves Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive…

Read More »

NEW WEBINAR | Empowering Patient Leaders: Understanding EU Health Policies

📌 Webinar Title: ‘‘Empowering Patient Leaders: Understanding EU Health Policies’’ 📌 Date & Time: 18 December 2023, Monday, at 14:00…

Read More »

Ms Katia Pelides

Read More »

CLINICAL NEWS | Agios Meets Clinical Proof-of-Concept in Anaemia Treatment for Adults with Lower-Risk MDS

On Monday, the specialized disease company announced the successful achievement of “proof-of-concept” in a Phase 2a trial involving AG-946, a…

Read More »

CASGEVY | 1st Gene-Editing Therapy for Thalassaemia and SCD Approved in UK

Casgevy is the first medicine to be licensed that uses the innovative gene-editing tool CRISPR, for which its inventors were…

Read More »